keyword
MENU ▼
Read by QxMD icon Read
search

HIV statin cardiovascular

keyword
https://www.readbyqxmd.com/read/28437620/american-association-of-clinical-endocrinologists-and-american-college-of-endocrinology-guidelines-for-management-of-dyslipidemia-and-prevention-of-cardiovascular-disease
#1
Paul S Jellinger, Yehuda Handelsman, Paul D Rosenblit, Zachary T Bloomgarden, Vivian A Fonseca, Alan J Garber, George Grunberger, Chris K Guerin, David S H Bell, Jeffrey I Mechanick, Rachel Pessah-Pollack, Kathleen Wyne, Donald Smith, Eliot A Brinton, Sergio Fazio, Michael Davidson
OBJECTIVE: The development of these guidelines is mandated by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees and adheres with published AACE protocols for the standardized production of clinical practice guidelines (CPGs). METHODS: Recommendations are based on diligent reviews of the clinical evidence with transparent incorporation of subjective factors, according to established AACE/ACE guidelines for guidelines protocols...
April 2017: Endocrine Practice
https://www.readbyqxmd.com/read/28416195/pitavastatin-versus-pravastatin-in-adults-with-hiv-1-infection-and-dyslipidaemia-intrepid-12-week-and-52-week-results-of-a-phase-4-multicentre-randomised-double-blind-superiority-trial
#2
Judith A Aberg, Craig A Sponseller, Douglas J Ward, Vladimir A Kryzhanovski, Stuart E Campbell, Melanie A Thompson
BACKGROUND: People living with HIV-1 infection are at greater risk for cardiovascular disease than seronegative adults. Treatment of dyslipidaemia with statins has been challenging in people with HIV because of an increased potential for drug interactions due to competing cytochrome P450 metabolism between statins and commonly used antiretroviral agents. Neither pitavastatin nor pravastatin depend on cytochrome P450 for primary metabolism. We aimed to assess the safety and efficacy of pitavastatin versus pravastatin in adults with HIV and dyslipidaemia...
April 13, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28364370/recommendations-for-managing-drug-drug-interactions-with-statins-and-hiv-medications
#3
REVIEW
Barbara S Wiggins, Donald G Lamprecht, Robert L Page, Joseph J Saseen
The discovery of antiretroviral therapy (ART) for the treatment of human immunodeficiency virus (HIV) has enabled individuals to live longer. As a result, HIV is now often considered a chronic condition. However, as a result of the increase in longevity or the HIV treatment modalities themselves, individuals with HIV are at high risk for the development of atherosclerotic cardiovascular disease. Therefore, these patients should be optimized with pharmacologic therapy to lower their cardiovascular risk through the addition of statin therapy to their regimen...
April 1, 2017: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/28265887/coronary-artery-disease-in-hiv-infected-patients-downside-of-living-longer
#4
REVIEW
John Charles A Lacson, Revery P Barnes, Hossein Bahrami
PURPOSE OF REVIEW: Introduction of combination antiretroviral therapy (ART) has increased the life expectancy of patients with HIV infection, allowing them to live longer with this chronic medical condition and consequently experiencing conditions such as cardiovascular diseases (CVDs). Several studies have investigated the increased risk of CVD in people living with HIV (PLWH). However, less is known about the exact mechanisms involved in this increased risk. Also, specific guidelines for management of CVD in PLWH have not been developed yet...
April 2017: Current Atherosclerosis Reports
https://www.readbyqxmd.com/read/28249009/current-use-of-statins-reduces-risk-of-hiv-rebound-on-suppressive-haart
#5
Henning Drechsler, Colby Ayers, James Cutrell, Naim Maalouf, Pablo Tebas, Roger Bedimo
BACKGROUND: Despite compelling evidence for activity against HIV-1 in vitro, a virologic effect of statins has not been shown in clinical studies. Given their short plasma half-lives, such an effect may be transient and only apparent during ongoing exposure. METHODS: We studied all HIV infected US-Veterans who started HAART 1995-2011, had a documented HIV viral load (VL) >1000 copies/mL, reached an undetectable VL on HAART, and had ≥1 follow-up VL within 13 months...
2017: PloS One
https://www.readbyqxmd.com/read/28208120/cardiovascular-complications-of-hiv-infection
#6
REVIEW
Marshall J Glesby
HIV-infected individuals are at increased risk for cardiovascular events. Widely used cardiovascular disease (CVD) risk calculators to determine indications for statin treatment are not well validated for use in the HIV-infecte population. Some experts advocate including HIV infection as an independent risk factor for CVD. The effects of antiretroviral therapy on lipid profiles and the potentially increased risk for cardiovascular events must be taken into account when selecting treatment for HIV-infected individuals...
December 2017: Topics in Antiviral Medicine
https://www.readbyqxmd.com/read/28182617/statins-in-hiv-infected-patients-potential-beneficial-effects-and-clinical-use
#7
Enrique Bernal, Mar Masiá, Irene Marín, Félix Gutiérrez
Patients living with HIV have an increased risk of cardiovascular disease that is considered to be the result of an interaction between traditional cardiovascular risk factors, particularly smoking and dyslipidemia, and persistent chronic inflammation and immune activation associated with HIV infection, along with side effects of antiretroviral therapy. In the general population, the administration of statins has been associated with a reduction in cardiovascular disease-associated mortality, and these drugs are among the most common class of medication prescribed in high-income countries...
February 9, 2017: AIDS Reviews
https://www.readbyqxmd.com/read/28121706/greater-remnant-lipoprotein-cholesterol-reduction-with-pitavastatin-compared-with-pravastatin-in-hiv-infected-patients
#8
Parag H Joshi, P Elliott Miller, Seth S Martin, Steven R Jones, Joseph M Massaro, Ralph B D'Agostino, Krishnaji R Kulkarni, Craig Sponseller, Peter P Toth
OBJECTIVE: Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in those with HIV. An emerging CVD risk factor is triglyceride-rich remnant lipoprotein cholesterol (RLP-C: the sum of intermediate-density lipoprotein and very low-density lipoprotein cholesterol). The effects of statin therapy on lipoprotein subfractions, including RLP-C, in HIV dyslipidemia are unknown. METHODS: This is a post hoc analysis of the randomized INTREPID trial (NCT 01301066) comparing pitavastatin 4 mg daily vs...
April 24, 2017: AIDS
https://www.readbyqxmd.com/read/28072892/use-of-statins-and-aspirin-to-prevent-cardiovascular-disease-among-hiv-positive-patients-a-survey-among-italian-hiv-physicians
#9
Paolo Maggi, Giuseppe Vittorio De Socio, Stefania Cicalini, Maurizio D'Abbraccio, Gabriella D'Ettorre, Antonio Di Biagio, Canio Martinelli, Giuseppe Nunnari, Stefano Rusconi, Laura Sighinolfi, Vincenzo Spagnuolo, Nicola Squillace
We conducted a survey among Italian HIV specialists to study the utilization of statins and aspirin, administering a questionnaire aimed at investigating their use, the use of guidelines and scores, and the management of interactions. The answers were uniform in the different geographic areas. The majority directly prescribe statins and 43% of them prescribe aspirin. The majority follows guidelines and utilize scores to calculate the CV risk. Our survey demonstrates the commitment and autonomy in prescribing statins and aspirin of Italian physicians...
January 10, 2017: New Microbiologica
https://www.readbyqxmd.com/read/28062146/intensive-statin-regimens-for-reducing-risk-of-cardiovascular-diseases-among-human-immunodeficiency-virus-infected-population-a-nation-wide-longitudinal-cohort-study-2000-2011
#10
Huang-Tz Ou, Kai-Cheng Chang, Chung-Yi Li, Chen-Yi Yang, Nai-Ying Ko
OBJECTIVE: This study evaluated the risk of cardiovascular diseases (CVD) in a statin-treated HIV-infected population and the effects of intensive statin regimens (i.e., high-dose or potency) on CVD risks. METHODS: 945 HIV-infected patients newly on statin treatment (144, 15.7% with CVD history) were identified from Taiwan's national HIV cohort. Using the median of the first year cumulative statin dosage as a cut-off point, patients were classified into either a high-dose or low-dose group...
March 1, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28045766/baseline-vitamin-d-deficiency-decreases-the-effectiveness-of-statins-in-hiv-infected-adults-on-antiretroviral-therapy
#11
Corrilynn O Hileman, Vin Tangpricha, Abdus Sattar, Grace A McComsey
OBJECTIVE: Vitamin D deficiency is common in HIV. Statins may increase vitamin D, and it is unknown whether vitamin D modifies the effect of statins on cardiovascular disease. DESIGN: SATURN-HIV was a 96-week, randomized, placebo-controlled trial designed to evaluate the effect of rosuvastatin on immune activation and subclinical vascular disease in HIV-infected adults on antiretroviral therapy. This analysis focuses on the prespecified secondary endpoint 25-hydroxyvitamin D [25(OH)D] concentrations...
April 15, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/28011249/lack-of-effects-of-statins-on-high-density-lipoprotein-subfractions-in-hiv-1-infected-patients-receiving-protease-inhibitors
#12
Randa Bittar, Élisabeth Aslangul, Philippe Giral, Lambert Assoumou, Marc-Antoine Valantin, Olga Kalmykova, Marie-Christine Federspiel, Corinne Cherfils, Dominique Costagliola, Dominique Bonnefont-Rousselot
BACKGROUND: We evaluated the effect of 45 days of rosuvastatin or pravastatin treatment on the distribution of HDL subfractions in HIV-1-infected individuals receiving boosted protease inhibitors (PIs) with cardiovascular risk. METHODS: The distribution of HDL subclasses by gradient gel electrophoresis was blindly assessed in 74 HIV-1-infected individuals receiving boosted PIs at baseline and at day 45 of statin treatment, and compared with the distribution obtained in 63 healthy normolipidemic individuals taken as controls...
February 2017: Comptes Rendus Biologies
https://www.readbyqxmd.com/read/28002550/assessing-and-refining-myocardial-infarction-risk-estimation-among-patients-with-human-immunodeficiency-virus-a-study-by-the-centers-for-aids-research-network-of-integrated-clinical-systems
#13
Matthew J Feinstein, Robin M Nance, Daniel R Drozd, Hongyan Ning, Joseph A Delaney, Susan R Heckbert, Matthew J Budoff, William C Mathews, Mari M Kitahata, Michael S Saag, Joseph J Eron, Richard D Moore, Chad J Achenbach, Donald M Lloyd-Jones, Heidi M Crane
Importance: Persons with human immunodeficiency virus (HIV) that is treated with antiretroviral therapy have improved longevity but face an elevated risk of myocardial infarction (MI) due to common MI risk factors and HIV-specific factors. Despite these elevated MI rates, optimal methods to predict MI risks for HIV-infected persons remain unclear. Objective: To determine the extent to which existing and de novo estimation tools predict MI in a multicenter HIV cohort with rigorous MI adjudication...
February 1, 2017: JAMA Cardiology
https://www.readbyqxmd.com/read/27831597/pharmacological-management-of-dyslipidemia-in-high-and-very-high-cardiovascular-risk-patients
#14
REVIEW
V Pascual Fuster
Dyslipaemia is one of the main risk factors in the development of cardiovascular diseases. Currently, there are different alternatives available (amongst which statins occupy a pre-eminent place), to optimise the treatment of patients at high or very high cardiovascular risk. Despite this, the percentage of patients that achieve good lipid control is low. The causes of the mismatch with proposed objectives include lack of patient adherence and therapeutic inertia. This review uses available evidence and the latest clinical guides as a basis to assess the pharmacological treatment of dyslipaemia in patients with a background of arteriosclerotic vascular disease, diabetes, chronic kidney disease, cardiovascular risk at ≥5% calculated by SCORE and familial hypercholesterolaemia...
December 2016: Revista Española de Sanidad Penitenciaria
https://www.readbyqxmd.com/read/27749649/safety-and-efficacy-of-atorvastatin-in-human-immunodeficiency-virus-infected-children-adolescents-and-young-adults-with-hyperlipidemia
#15
Ann J Melvin, Grace Montepiedra, Lisa Aaron, William A Meyer, Hans M Spiegel, William Borkowsky, Mark J Abzug, Brookie M Best, Marilyn J Crain, Peggy R Borum, Bobbie Graham, Patricia Anthony, Katherine Shin, George K Siberry
BACKGROUND: Human immunodeficiency virus (HIV)-infected children receiving antiretroviral therapy (ART) have increased prevalence of hyperlipidemia and risk factors for cardiovascular disease. No studies have investigated the efficacy and safety of statins in this population. METHODS: HIV-infected youth 10 to <24 years of age on stable ART with low-density lipoprotein cholesterol (LDL-C) ≥130 mg/dL for ≥6 months initiated atorvastatin 10 mg once daily...
January 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/27695357/update-on-current-management-of-chronic-kidney-disease-in-patients-with-hiv-infection
#16
REVIEW
Nina E Diana, Saraladevi Naicker
The prevalence of HIV-associated chronic kidney disease (CKD) varies geographically and depends on the definition of CKD used, ranging from 4.7% to 38% globally. The incidence, however, has decreased with the use of effective combined antiretroviral therapy (cART). A wide variety of histological patterns are seen in HIV-associated kidney diseases that include glomerular and tubulointerstitial pathology. In resource-rich settings, there has been a plateau in the incidence of end-stage renal disease secondary to HIV-associated nephropathy (HIVAN)...
2016: International Journal of Nephrology and Renovascular Disease
https://www.readbyqxmd.com/read/27631189/pharmacogenomics-of-rosuvastatin-a-glocal-global-local-african-perspective-and-expert-review-on-a-statin-drug
#17
Nyarai D Soko, Collen Masimirembwa, Collet Dandara
The incidence of cardiovascular diseases (CVDs) in African populations residing in the African continent is on the rise fueled by both a steady increase in CVD risk factors and comorbidities such as human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS), tuberculosis, and parasitic diseases such as bilharzia. Statins are recommended together with lifestyle changes in the treatment of hypercholesterolemia and overall reduction of cardiovascular events. Rosuvastatin in particular is an attractive candidate in the management of CVDs in African populations often plagued with multimorbidities owing to both its potency and low drug-to-drug interaction potential...
September 2016: Omics: a Journal of Integrative Biology
https://www.readbyqxmd.com/read/27625435/cardiovascular-disease-statins-and-hiv
#18
Allison Ross Eckard, Eric G Meissner, Inderjit Singh, Grace A McComsey
Human immunodeficiency virus (HIV)-infected patients are at an increased risk of serious, non-AIDS-defining comorbidities, even in the setting of viral suppression with combination antiretroviral therapy. This increased risk is due in part to immune dysfunction and heightened inflammation and immune activation associated with chronic HIV infection. Statins have wide-reaching immunomodulatory effects, and their use in the HIV-infected population may be of particular benefit. In this article, we review the pathogenesis of increased inflammation during HIV infection and how it contributes to the risk of cardiovascular disease among HIV-infected individuals...
October 1, 2016: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/27611626/cardiovascular-risk-in-hiv-infected-and-uninfected-postmenopausal-minority-women-use-of-the-framingham-risk-score
#19
Yamnia I Cortés, Nancy Reame, Cosmina Zeana, Haomiao Jia, David C Ferris, Elizabeth Shane, Michael T Yin
OBJECTIVE: To characterize and compare cardiovascular disease (CVD) risk in HIV-infected and uninfected postmenopausal minority women using the Framingham Risk Score (FRS) as an assessment measure. METHODS: A cross-sectional analysis was performed in 152 (109 HIV+, 43 HIV-) subjects from an existing study cohort of postmenopausal Hispanic and African American women. Data necessary to calculate FRS and menopause features were retrieved by retrospective chart review...
March 2017: Journal of Women's Health
https://www.readbyqxmd.com/read/27500282/rosuvastatin-decreases-intestinal-fatty-acid-binding-protein-i-fabp-but-does-not-alter-zonulin-or-lipopolysaccharide-binding-protein-lbp-levels-in-hiv-infected-subjects-on-antiretroviral-therapy
#20
Nicholas T Funderburg, Morgan Boucher, Abdus Sattar, Manjusha Kulkarni, Danielle Labbato, Bruce I Kinley, Grace A McComsey
INTRODUCTION: Altered gastrointestinal (GI) barrier integrity and subsequent microbial translocation may contribute to immune activation in HIV infection. We have reported that rosuvastatin improved several markers of immune activation in HIV+ participants, but the effect of statin treatment on markers of GI barrier dysfunction is unknown. METHODS: SATURN-HIV is a randomized, double-blind, placebo-controlled trial assessing the effect of rosuvastatin (10mg/daily) on markers of cardiovascular disease, inflammation, and immune activation in ART-treated patients...
2016: Pathogens & Immunity
keyword
keyword
14739
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"